UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000063676
Receipt number R000072877
Scientific Title Japanese Patient Preferences for Bladder Sparing Therapies in Non Muscle Invasive Bladder Cancer NMIBC A Discrete Choice Experiment
Date of disclosure of the study information 2026/11/20
Last modified on 2026/11/18 12:37:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Japanese Patient Preferences for Bladder Sparing Therapies in Non Muscle Invasive Bladder Cancer NMIBC A Discrete Choice Experiment

Acronym

NA

Scientific Title

Japanese Patient Preferences for Bladder Sparing Therapies in Non Muscle Invasive Bladder Cancer NMIBC A Discrete Choice Experiment

Scientific Title:Acronym

NA

Region

Japan


Condition

Condition

Non-Muscle-Invasive Bladder Cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To quantify patient preferences for the efficacy, safety, and administration attributes of bladder-sparing therapies for NMIBC.

Basic objectives2

Others

Basic objectives -Others

Patient preferences (relative preference weights for treatment attributes of bladder-sparing therapies)

Trial characteristics_1

Others

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

A set of relative preference weights and 95% confidence intervals for all attribute levels included in the DCE survey instrument.

Key secondary outcomes

Secondary: Preference weights for the prespecified Priority Enrollment Group (*1), subject to analytical feasibility criteria prespecified in the SAP; conditional relative importance of each attribute; MAR/MAB; and predicted-choice probabilities.
*1. A clinically relevant, prespecified subgroup reflecting the post-BCG treatment decision context. Participants must meet both of the following participant-reported criteria: (A) information they report having received from a physician supporting high-risk NMIBC; and (B) information they report having received from a physician supporting disease persistence or recurrence following BCG treatment, insufficient BCG response, medical unsuitability of further BCG, including BCG intolerance, treatment-limiting toxicity, or another medical reason, or insufficient expected clinical benefit of further BCG, or the need to consider treatment modification. This is an operational study classification based on participant-reported information and is not equivalent to a medically confirmed diagnosis or regulatory classification of BCG-unresponsive NMIBC.

Exploratory: Preference heterogeneity by patient background factors (subgroup analysis); latent class analysis; descriptive preferences for bladder-sparing therapies relative to RC based on direct elicitation.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Aged 18 years or older at the time of providing informed consent.
2)Is able to understand the study information, provide informed consent personally, and complete the applicable interview or survey independently without a proxy respondent.
3)Resident of Japan
4)Self-reported diagnosis of NMIBC
5)Has undergone TURBT
6)Has previously received BCG intravesical treatment

Key exclusion criteria

1) Has undergone radical cystectomy.
2) Has previously received or is currently receiving a novel bladder-sparing treatment for NMIBC (see definition below).
3) Has made a final decision to receive a specific novel bladder-sparing treatment for NMIBC, regardless of whether the treatment initiation, administration, or procedure has already been scheduled.
For the purpose of these criteria, a novel bladder-sparing treatment refers to a treatment given after BCG treatment to preserve the bladder, other than intravesical BCG therapy and conventional intravesical chemotherapy (including immediate postoperative instillation), for example, intravesical gene therapy or an intravesical drug-delivery system. Unapproved treatments and treatments given in clinical trials or clinical research are also included. Receiving information about, considering, or being recommended a treatment without having made a final decision, and prior TURBT alone, are not exclusionary.

Target sample size

215


Research contact person

Name of lead principal investigator

1st name Atsushi
Middle name
Last name Nakano

Organization

Ferring Pharmaceuticals Co., Ltd.

Division name

Medical Affairs

Zip code

105-0001

Address

10F The Okura Prestige Tower, 2-10-4 Toranomon, Minato-ku, Tokyo 105-0001, Japan

TEL

03-5544-9237

Email

Atsushi.Nakano@ferring.com


Public contact

Name of contact person

1st name Takako
Middle name
Last name Yuki

Organization

3H Medi Solution Inc.

Division name

Insight Solution Promotion Office

Zip code

171-0022

Address

1-13-23 Minami-Ikebukuro, Toshima-ku, Tokyo

TEL

03-5953-2108

Homepage URL


Email

research_info_or@3h-ms.co.jp


Sponsor or person

Institute

Ferring Pharmaceuticals Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Ferring Pharmaceuticals Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Japan Conference of Clinical Research

Address

1-13-23 Minami-Ikebukuro, Toshima-ku, Tokyo 171-0022, Japan

Tel

03-6868-7022

Email

jccr-info@jccr.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 11 Month 04 Day

Date of IRB

2026 Year 11 Month 19 Day

Anticipated trial start date

2026 Year 11 Month 24 Day

Last follow-up date

2027 Year 09 Month 06 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Protocol number EG-26-81

This is a non-interventional, cross-sectional, web-based survey using a discrete-choice experiment (DCE) in patients with NMIBC and a history of intravesical BCG therapy. Treatment attributes of bladder-sparing therapies related to efficacy, safety, and administration will be evaluated, and patients' relative preference weights for each attribute level will be estimated using a random-parameters logit model. The survey instrument will be finalized through formative qualitative interviews (approx. 10 participants) and a pretest (approx. 5 participants), followed by the main survey (approx. 200 participants).


Management information

Registered date

2026 Year 11 Month 18 Day

Last modified on

2026 Year 11 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072877